Trial Profile
Phase II study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Nov 2011 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 03 Jun 2011 New trial record